


Atty. Docket No. 014811-215.116
Application. No. 10/525,290

Amendments to the Claims:

This listing of claims will replace the version submitted on August 10, 2007.

1. (Currently amended) An activated compound having a formula:



wherein ~~the an activated compound moiety~~ an activated compound moiety is attached to the hydroxyl group and wherein the activated moiety comprises an activating moiety is selected from the group consisting of chloroformate, NHS carbonate, DSC para-nitrochloroformate, p-nitrochloroformate, phosgene and paranitrophenyl carbonate, and

where

R¹ is selected from the group consisting of alkyl, -CH₂(OC₂H₄)OCH₃, and -(OC₂H₄)OCH₃;


n is 0-4;

Olig is an oligomer having a formula:



where:

L is a optional linker moiety selected from the group consisting of -CH₂O-, -CH₂OX-, -OX-, -C(O)-, -C(O)X, -NH-, -NHC(O)-, -XNHC(O)-, -NHC(O)X, -C(O)NH-, -C(O)NHX-, and



where:

X is alkyl₁₋₆ or is not present,

Atty. Docket No. 014811-215.116
Application. No. 10/525,290

Y is N or O or is not present, and

R³ is alkyl₁₋₆;

PAG is a linear or branched polyalkylene glycol moiety;

R² is an alkyl₁₋₂₂ capping moiety if X is present or alkyl₂₋₂₂ if X is not present;

q is a number from 1 to 10 ~~the maximum number of branches on PAG~~; and

m is 1-5.

2. (Original) The compound of claim 1 comprising an Olig coupled to carbon 4 of the phenol moiety.
3. (Original) The compound of claim 1 comprising an Olig coupled to carbon 3 of the phenol moiety, and/or an Olig coupled to carbon 5 of the phenol moiety.
4. (Original) The compound of claim 1 wherein m is 1 and the Olig is coupled to carbon 4 of the phenol moiety.
5. (Original) The compound of claim 1 wherein m is 1 and the Olig is coupled to carbon 3 or carbon 5 of the phenol moiety.
6. (Original) The compound of claim 1 wherein:
 - (a) m is 2, and
 - (b) a first Olig is coupled to carbon 3 of the phenol moiety, and
 - (c) a second Olig is coupled to carbon 5 of the phenol moiety.
7. (Original) The compound of claim 1 wherein L is present and X is not present.
8. (Original) The compound of claim 1 wherein L and X are both present.
9. (Original) The compound of claim 1 wherein PAG is a linear polyalkylene glycol moiety.
10. (Original) The compound of claim 1 wherein PAG is a linear polyethylene glycol moiety.

Atty. Docket No. 014811-215.116
Application. No. 10/525,290

11. (Original) The compound of claim 1 wherein PAG is a branched polyalkylene glycol moiety.
12. (Original) The compound of claim 1 wherein PAG is a branched polyethylene glycol moiety.
13. (Original) The compound of claim 1 wherein q is 1 to 5.
14. (Original) The compound of claim 1 wherein q is 2.
15. (Original) The compound of claim 1 wherein R² is alkyl₅₋₁₂.
16. (Original) The compound of claim 1 wherein R² is alkyl₁₋₄.
17. (Original) The compound of claim 1 wherein X is present and R² is methyl.
18. (Original) The compound of claim 1 wherein R¹ is alkyl₁₋₂₂.
19. (Original) The compound of claim 1 wherein R¹ is alkyl₁₋₁₂.
20. (Original) The compound of claim 1 wherein R¹ is alkyl₁₋₆.
21. (Original) The compound of claim 1 wherein R¹ is methyl and L is not amide or O.
22. (Original) The compound of claim 1 wherein R¹ is methyl.
23. (Cancelled)
24. (Cancelled)
25. (Currently amended) The activated compound of claim 1 further comprising a protein drug moiety, wherein the protein drug moiety is insulin. A biologically active agent comprising a compound of claim 1 covalently coupled thereto by a carbamate bond to form a prodrug which does or does not retain the biological activity of the biologically active agent, wherein the biologically active agent is a drug moiety or a protein drug moiety.

Atty. Docket No. 014811-215.116
Application. No. 10/525,290

26. (Cancelled)

27. (Cancelled)

28. (Cancelled)

29. (Cancelled) :

30. (Cancelled)

31. (Cancelled)


32. (Cancelled)

33. (Cancelled)

34. (Cancelled)

35. (Cancelled)

36. (Currently amended) A compound having a formula:



Atty. Docket No. 014811-215.116
Application. No. 10/525,290

wherein

X is an alkyl or is not present;

PEG is linear or branched PEG₂₋₅₀;

R is H or alkyl;

n is from 1 to 10 the maximum number of PEG branches; and

R¹ is alkyl.

37. (Cancelled)

38. (Cancelled)


39. (Cancelled)

40. (Cancelled)

41. (Cancelled)

42. (Cancelled)

43. (Previously presented) A compound having a formula:



(Compound 7).

44. (Original) The compound of claim 1, wherein the compound is a pure prodrug or partial prodrug.

45. (Original) A pharmaceutical composition comprising the compound of claim 1 in a pharmaceutically acceptable carrier.

Atty. Docket No. 014811-215.116
Application. No. 10/525,290

46. (Cancelled)


47. (Previously presented) A method of treating a subject in need of treatment for diabetes comprising administering an effective amount of the compound of claim 1 that is conjugated to insulin to the subject.

Atty. Docket No. 014811-215.116
Application. No. 10/525,290

Conclusion

In the event that any issues remain, Examiner Nwaonicha is requested to contact the undersigned attorney at (919) 286-8089 to resolve same.

Respectfully submitted,



Date: September 20, 2007

Marianne Fuierer
Registration No. 39,983
Attorney for Applicants
Moore & Van Allen